Lenalidomide promotes the development of <i>TP53</i>-mutated therapy-related myeloid neoplasmsAdam S. Sperling, Koichi Takahashi, Veronica Guerra et al.|Blood|2022Cited by 138
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in miceEmma C. Fink, Benjamin L. Ebert, Andrew A. Guirguis et al.|Blood|2018Cited by 126